Gemcitabine Hydrochloride Market Report 2026

Gemcitabine Hydrochloride Market Overview

• Gemcitabine Hydrochloride market size has reached to $0.83 billion in 2025 • Expected to grow to $1.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Incidence Of Breast Cancer Driving The Growth Of The Market Due To Increasing Risk With Aging And Genetic Mutations • Market Trend: Advancements In Perioperative Immunotherapy Transforming Cancer Treatment Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gemcitabine Hydrochloride Market?

Gemcitabine hydrochloride is a synthetic nucleoside analog that interferes with DNA synthesis, thereby inhibiting cell division. It is commonly used in research involving cellular replication due to its ability to integrate into DNA strands and block the progression of the replication process. Once inside the cell, it undergoes phosphorylation to become active and is incorporated into DNA, leading to chain termination and triggering programmed cell death. The main products of gemcitabine hydrochloride include injections, solutions, and others. Injection refers to a form of gemcitabine hydrochloride that is administered directly into the bloodstream using a syringe or IV. It can be administered through intravenous injection, subcutaneous injection, and intramuscular injection and is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. It is applied for pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and others.

What Is The Gemcitabine Hydrochloride Market Growth Forecast?

The gemcitabine hydrochloride market size is expected to see strong growth in the next few years. It will grow to $1.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growth of combination oncology therapies, expansion of cancer care infrastructure, rising prevalence of solid tumors, development of biosimilars, increasing oncology drug access. Major trends in the forecast period include increasing use in combination chemotherapy, rising demand for injectable oncology drugs, expansion of hospital-based cancer treatments, growing focus on precision oncology, increasing adoption in multiple cancer types.

Global Gemcitabine Hydrochloride Market Segmentation

1) By Product Type: Injection, Solution, Other Product Types 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics 3) By Application: Pancreatic Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Breast Cancer, Ovarian Cancer, Other Applications Subsegments: 1) By Injection: Single-Dose Vials, Multi-Dose Vials, Prefilled Syringes 2) By Solution: Ready-To-Use Liquid Solutions, Concentrated Solutions For Dilution 3) By Other Product Types: Lyophilized Powder, Combination Formulations With Other Chemotherapeutic Agents

What Is The Driver Of The Gemcitabine Hydrochloride Market?

The rising incidence of breast cancer is anticipated to propel the growth of the gemcitabine hydrochloride market going forward. Breast cancer refers to a type of cancer that begins in the cells of the breast, typically in the milk ducts or glands. The increasing life expectancy contributes to the rise in breast cancer cases, as aging allows more time for genetic mutations to accumulate, elevating the risk of developing the disease. Gemcitabine hydrochloride is required for breast cancer treatment as it interferes with DNA replication, effectively slowing the rapid division of abnormal cells. For instance, in February 2025, according to the International Agency For Research On Cancer, a US-based health organization, it is expected that there will be 3.2 million breast cancer new cases per year by 2050. Therefore, the rising incidence of breast cancer will drive the growth of the gemcitabine hydrochloride industry.

Key Players In The Global Gemcitabine Hydrochloride Market

Major companies operating in the gemcitabine hydrochloride market are Fresenius Kabi, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Mylan NV, Accord Healthcare, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy’s Laboratories, Cipla Ltd., Amneal Pharmaceuticals, Alkem Laboratories, Gland Pharma Ltd., Strides Pharma Science Ltd., Shilpa Medicare Ltd., ScinoPharm Taiwan Ltd., Orchid Pharma Ltd., Arevipharma GmbH, Qilu Pharmaceutical Co. Ltd.

Global Gemcitabine Hydrochloride Market Trends and Insights

Major companies operating in the gemcitabine hydrochloride market are focusing on developing advanced therapies, such as perioperative immunotherapy, to enhance treatment efficacy. Perioperative immunotherapy refers to cancer treatment given before (neoadjuvant) and after (adjuvant) surgery to improve outcomes and reduce recurrence. For instance, in March 2025, AstraZeneca is a UK-based pharmaceutical company, received the US Food and Drug Administration (FDA) approval for Imfinzi (durvalumab). This marks the first and only perioperative immunotherapy approved for treating muscle-invasive bladder cancer (MIBC). The treatment combines Imfinzi with chemotherapy (gemcitabine and cisplatin) before surgery and continues with Imfinzi alone afterward. Clinical trials showed improved survival and reduced recurrence risks.

What Are Latest Mergers And Acquisitions In The Gemcitabine Hydrochloride Market?

In December 2024, Cheplapharm, a Germany-based pharmaceutical company, acquired Gemzar from Eli Lilly for an undisclosed amount. This acquisition strengthens CHEPLAPHARM's oncology portfolio by incorporating the widely used chemotherapy drug, Gemzar, which is effective in treating various cancers such as non-small cell lung cancer, pancreatic cancer, and breast cancer. Eli Lilly and Company is a US-based manufacturer of gemcitabine hydrochloride, also known as Gemzar.

Regional Insights

North America was the largest region in the gemcitabine hydrochloride market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gemcitabine Hydrochloride Market?

The gemcitabine hydrochloride market consists of sales of pharmaceutical intermediates, generic injectable drugs, and formulation development kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gemcitabine Hydrochloride Market Report 2026?

The gemcitabine hydrochloride market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gemcitabine hydrochloride industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.